IPOD-B3: Interventions for Postoperative Delirium: Biomarker-3

Sponsor
University of Wisconsin, Madison (Other)
Overall Status
Recruiting
CT.gov ID
NCT03124303
Collaborator
National Institute on Aging (NIA) (NIH)
310
1
105.6
2.9

Study Details

Study Description

Brief Summary

The IPOD-B3 study aims to characterize the relationship between premorbid brain activity and postoperative delirium in patients undergoing major surgery. This is a expansion of the NeuroVISION Bolt-On study, NCT01980511.

Condition or Disease Intervention/Treatment Phase
  • Procedure: High Density-Electroencephalogram
  • Procedure: Magnetic Resonance Imaging

Detailed Description

9/8/21-- Deleted two Outcome Measures pending IRB approval.

11/5/21-- added outcome measures after IRB approval.

Study Design

Study Type:
Observational
Anticipated Enrollment :
310 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Interventions for Postoperative Delirium: Biomarker-3
Actual Study Start Date :
Feb 13, 2017
Anticipated Primary Completion Date :
Dec 1, 2024
Anticipated Study Completion Date :
Dec 1, 2025

Outcome Measures

Primary Outcome Measures

  1. Functional Connectivity [Pre-operative measure: Up to 4 weeks prior to surgery. Post-operative measure: Post-Operative days 1-4]

    Change from baseline functional connectivity at immediate postoperative period and association between delirium (CAM) and functional connectivity of the cingulate cortex

Secondary Outcome Measures

  1. Inflammation [Pre-operative measure: Up to 4 weeks prior to surgery. Post-operative measure: POD1-4]

    Assess the changes from preoperative to postoperative EEG associated with delirium and change in plasma/cerebrospinal fluid (CSF) IL-6 or other biomarkers (e.g. other cytokines or markers of neronal injury)

  2. Biomarkers [Post-operative day 1 through 4]

    Identify biomarkers of delirium and neural damage through changes in circulating plasma proteins and molecules (through mass spectometry)

  3. Brain measurements [Preoperative MRI will occur up to 4-weeks prior to surgery. Delirium is followed postoperatively, days 1-4]

    Assess the association between preoperative white matter connectivity (DTI) and cortical thickness (derived from MRI) and postoperative delirium

  4. Long term cognition [Pre-operative cognition measures will occur up to 4 weeks prior to surgery. Post-operative delirium measured on postoperative days 1-4. Long term post-operative cognition measured 1 year after surgery.]

    Examine the incidence of delirium with change in cognition from preoperatively to one-year postoperatively.

  5. Long term cognition [Pre-operative measure: Up to 4 weeks prior to surgery. Post-operative measure: Up to two years after surgery]

    Assess the impact of delirium, preoperative and postoperative imaging biomarkers with a change in long term cognition

  6. Baseline cognition, specific and global. [Cognition is assessed preoperatively. Participants are followed for delirium on postoperative days 1-4]

    Examine the association between preoperative cognition using a neuropsychological battery, and postoperative delirium incidence.

  7. Biomarkers and brain measurements [Pre-op measures: up to 4 weeks prior to surgery. Post-op measures: one year, and two years, after surgery.]

    Assess the changes in cognition and biomarkers over one year with EEG changes.

  8. Representativeness of surgical population [Pre-op MRI: up to 4 weeks prior to surgery.]

    Identify whether patients who consent to the MRI are reflective of the surgical population.

  9. Genetics and delirium [Pre-op blood collected up to 4 weeks prior to surgery. Post-operative delirium measured on postoperative days 1-4. Post-operative blood collected on postoperative days 1-4. Long term blood collected 90 days and 1 year after surgery.]

    Identify genetic and epigenetic changes associated with delirium and its pathogenesis.

  10. Postoperative amyloid beta deposition and delirium [Post-operative delirium measured on postoperative days 1-4. PET imaging will occur 90 days after surgery.]

    Identify associations between delirium and amyloid beta deposition detected by Positron Emission Tomography at 90 days after surgery in sub-study IPOD-PET.

  11. Long term changes in amyloid beta deposition and delirium [Pre-operative PET imaging will occur up to 4 weeks prior to surgery. Post-operative delirium measured on postoperative days 1-4. Post-operative PET imaging will occur 1 year after surgery.]

    Identify associations between delirium and amyloid beta deposition detected by Positron Emission Tomography preoperatively and 1 year after surgery in sub-study IPOD-PET2.

  12. Long term cognition [Pre-operative cognition measures will occur up to 4 weeks prior to surgery. Long term post-operative cognition measured 2 years after surgery.]

    Identify predictors of delirium severity and incidence, for change in cognition from preoperatively to two-years postoperatively.

Eligibility Criteria

Criteria

Ages Eligible for Study:
65 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Age ≥65 years

  • Anticipated length of hospital stay of at least 2 days after surgery that occurs under general or neuraxial anesthesia

  • Written Informed Consent for potential participation prior to surgery

Exclusion Criteria:
  • Contraindication to MRI or EEG (e.g. implanted devices not safe for MRI studies, claustrophobia, unable to lie flat or still),

  • Unable or unwilling to attend the follow-up appointments,

  • Documented history of dementia

  • Residing in a nursing home,

  • Undergoing intracranial surgery

  • Unable to complete neurocognitive testing due to language, vision or hearing impairment,

  • Unable to communicate with the research staff due to language barriers,

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of Wisconsin-Madison Madison Wisconsin United States 53792

Sponsors and Collaborators

  • University of Wisconsin, Madison
  • National Institute on Aging (NIA)

Investigators

  • Principal Investigator: Robert Pearce, MD, PhD, University of Wisconsin, Madison

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University of Wisconsin, Madison
ClinicalTrials.gov Identifier:
NCT03124303
Other Study ID Numbers:
  • 2015-0374
  • A530900
  • SMPH\ANESTHESIOLOGY
  • 1K23AG055700-01A1
  • 1R01AG063849-01
  • Protocol Version 8/1/2022
First Posted:
Apr 21, 2017
Last Update Posted:
Aug 16, 2022
Last Verified:
Aug 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Product Manufactured in and Exported from the U.S.:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 16, 2022